Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Transcriptional and Microenvironmental Regulation of Lineage Ambiguity in Leukemia.

Hu T, Murdaugh R, Nakada D.

Front Oncol. 2017 Nov 6;7:268. doi: 10.3389/fonc.2017.00268. eCollection 2017. Review.

2.

SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models.

Hengst JA, Dick TE, Sharma A, Doi K, Hegde S, Tan SF, Geffert LM, Fox TE, Sharma AK, Desai D, Amin S, Kester M, Loughran TP, Paulson RF, Claxton DF, Wang HG, Yun JK.

Cancer Transl Med. 2017 Jul-Aug;3(4):109-121. doi: 10.4103/ctm.ctm_7_17. Epub 2017 Aug 14.

3.

Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy.

Perna F, Sadelain M.

Transl Cancer Res. 2016 Aug;5(Suppl 2):S221-S225. doi: 10.21037/tcr.2016.08.15. No abstract available.

4.

The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.

Mizukawa B, O'Brien E, Moreira DC, Wunderlich M, Hochstetler CL, Duan X, Liu W, Orr E, Grimes HL, Mulloy JC, Zheng Y.

Blood. 2017 Sep 14;130(11):1336-1346. doi: 10.1182/blood-2016-12-758458. Epub 2017 Aug 4.

PMID:
28778865
5.

Lentiviral Fluorescent Genetic Barcoding for Multiplex Fate Tracking of Leukemic Cells.

Maetzig T, Ruschmann J, Sanchez Milde L, Lai CK, von Krosigk N, Humphries RK.

Mol Ther Methods Clin Dev. 2017 Jun 1;6:54-65. doi: 10.1016/j.omtm.2017.05.007. eCollection 2017 Sep 15.

6.

The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.

Lin S, Luo RT, Shrestha M, Thirman MJ, Mulloy JC.

Blood. 2017 Aug 17;130(7):903-907. doi: 10.1182/blood-2017-04-777185. Epub 2017 Jun 21.

7.

The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia.

Rio-Machin A, Gómez-López G, Muñoz J, Garcia-Martinez F, Maiques-Diaz A, Alvarez S, Salgado RN, Shrestha M, Torres-Ruiz R, Haferlach C, Larráyoz MJ, Calasanz MJ, Fitzgibbon J, Cigudosa JC.

Leukemia. 2017 Sep;31(9):2000-2005. doi: 10.1038/leu.2017.194. Epub 2017 Jun 20. No abstract available.

8.

CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo.

Reimer J, Knöß S, Labuhn M, Charpentier EM, Göhring G, Schlegelberger B, Klusmann JH, Heckl D.

Haematologica. 2017 Sep;102(9):1558-1566. doi: 10.3324/haematol.2017.164046. Epub 2017 Jun 1.

9.

Modeling the process of human tumorigenesis.

Balani S, Nguyen LV, Eaves CJ.

Nat Commun. 2017 May 25;8:15422. doi: 10.1038/ncomms15422. Review. No abstract available.

10.

Dysregulation of haematopoietic stem cell regulatory programs in acute myeloid leukaemia.

Basilico S, Göttgens B.

J Mol Med (Berl). 2017 Jul;95(7):719-727. doi: 10.1007/s00109-017-1535-3. Epub 2017 Apr 20. Review.

11.

Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.

Chen X, Clark J, Wunderlich M, Fan C, Davis A, Chen S, Guan JL, Mulloy JC, Kumar A, Zheng Y.

Autophagy. 2017 May 4;13(5):955-966. doi: 10.1080/15548627.2017.1287652. Epub 2017 Feb 15.

PMID:
28282266
12.

MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.

Winters AC, Bernt KM.

Front Pediatr. 2017 Feb 9;5:4. doi: 10.3389/fped.2017.00004. eCollection 2017. Review.

13.

Mouse models of MLL leukemia: recapitulating the human disease.

Milne TA.

Blood. 2017 Apr 20;129(16):2217-2223. doi: 10.1182/blood-2016-10-691428. Epub 2017 Feb 8. Review.

14.

CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27kip1 signaling.

Zhang F, Liu X, Chen C, Zhu J, Yu Z, Xie J, Xie L, Bai H, Zhang Y, Fang X, Gu H, Wang C, Weng W, Zhang CC, Chen GQ, Liang A, Zheng J.

Haematologica. 2017 Apr;102(4):707-718. doi: 10.3324/haematol.2016.151555. Epub 2017 Jan 25.

15.

Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia.

Goyama S, Shrestha M, Schibler J, Rosenfeldt L, Miller W, O'Brien E, Mizukawa B, Kitamura T, Palumbo JS, Mulloy JC.

Oncogene. 2017 May 4;36(18):2589-2598. doi: 10.1038/onc.2016.416. Epub 2016 Nov 7.

PMID:
27819671
16.

Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.

Lin S, Wei J, Wunderlich M, Chou FS, Mulloy JC.

Oncotarget. 2016 Aug 30;7(35):55939-55950. doi: 10.18632/oncotarget.11093.

17.

Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.

Link KA, Lin S, Shrestha M, Bowman M, Wunderlich M, Bloomfield CD, Huang G, Mulloy JC.

Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9075-80. doi: 10.1073/pnas.1524225113. Epub 2016 Jul 25.

18.

Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche.

Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, Jordan CT.

Cell Stem Cell. 2016 Jul 7;19(1):23-37. doi: 10.1016/j.stem.2016.06.001. Epub 2016 Jun 30.

19.

S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance.

Ghosh J, Kobayashi M, Ramdas B, Chatterjee A, Ma P, Mali RS, Carlesso N, Liu Y, Plas DR, Chan RJ, Kapur R.

J Clin Invest. 2016 Jul 1;126(7):2621-5. doi: 10.1172/JCI84565. Epub 2016 Jun 13.

20.

Context matters in MLL-AF9-driven leukemias.

Park CY.

Blood. 2016 May 12;127(19):2268-9. doi: 10.1182/blood-2016-03-704338. No abstract available.

Supplemental Content

Support Center